User profiles for J. L. CALLEJAS

José Luis Calleja

Hospital Universitario Puerta de Hierro Majadahonda
Verified email at uam.es
Cited by 16790

Historical epidemiology of hepatitis C virus (HCV) in selected countries

…, AJ Blasco, M Buti, F Calinas, JL Calleja… - Journal of viral …, 2014 - Wiley Online Library
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New
treatment options are becoming available, and there is a need to characterize the …

Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.

CR JL, SM JA - Clinical and experimental rheumatology, 2009 - europepmc.org
Objective Rituximab is an anti-CD20 monoclonal antibody targeting B cells, which has been
used with success in a wide variety of autoimmune diseases. The experience with this drug …

[PDF][PDF] Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

…, N Ortego-Centeno, R Ríos, JL Callejas… - The American Journal of …, 2014 - cell.com
In this study, 1,833 systemic sclerosis (SSc) cases and 3,466 controls were genotyped with
the Immunochip array. Classical alleles, amino acid residues, and SNPs across the human …

Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

…, J Martin, BA Pons-Estel, JM Sabio, JL Callejas… - Genes & …, 2011 - nature.com
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disorder with a complex
pathogenesis in which genetic, hormonal and environmental factors have a role. Rare …

Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)

…, G Fraile, R Pérez-Alvarez, JL Callejas… - …, 2014 - academic.oup.com
Objective. To evaluate systemic involvement in primary SS in a large cohort of Spanish
patients using the EULAR-SS disease activity index (ESSDAI) definitions. Methods. Systemic …

[PDF][PDF] A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

…, R Ríos-Fernández, JL Callejas… - The American Journal of …, 2015 - cell.com
We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic
immune-mediated vasculitis. A case-control cohort, comprising 1,651 case subjects with GCA and …

[PDF][PDF] Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

…, E De Ramon, JL Callejas… - Clinical & …, 2010 - clinexprheumatol.org
… de Ramón3, JL Callejas4, A. Martínez-Berriotxoa5, L. Pallarés6, L. … García-Hernández,
MD, PhD Enrique de Ramón, MD, PhD José Luis Callejas, MD, PhD Agustín Martínez-Berriotxoa …

[HTML][HTML] Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on …

…, F Pasquau, E Fonseca, M Zamora, JL Callejas… - Medicine, 2017 - journals.lww.com
The aim of this study was to describe the clinical characteristics of ANCA-associated vasculitides
(AAV) at presentation, in a wide cohort of Spanish patients, and to analyze the impact of …

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

…, R Vilana, A Darnell, M Varela, B Sangro, JL Calleja… - Journal of …, 2016 - Elsevier
Background & Aims The success of direct-acting antivirals (DAA) against hepatitis C is a
major breakthrough in hepatology. Until now, however, there are very few data on the effect of …

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

D Perra, MA Alba, JL Callejas, M Mesquida… - …, 2012 - academic.oup.com
Objective. To describe the experience of two tertiary Spanish centres (Hospital Clínico San
Cecilio, Granada and Hospital Clínic, Barcelona) with the use of adalimumab for the …